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Background: Leukemia is the most common malignant proliferative disease in children. Our previous study found
that miR-99a was up-regulated in pediatric primary AML using microRNA expression profiles. Up to date, although
there is a certain number of reports on microRNA expression features and functions in pediatric acute myeloid
leukemia (AML) and chronic myeloid leukemia (CML), the expression and function of miR-99a in these diseases
remain to be investigated.
Methods: qRT-PCR was performed to measure the expression level of miR-99a in 88 samples including 68 pediatric
acute myeloid leukemia patients, 8 chronic myeloid leukemia patients and 12 pediatric controls. MTT assay,
apoptosis assay, dual-luciferase reporter transfection assay and western blot analysis were used to investigate the
function of miR-99a.
Results: MiR-99a was highly expressed in pediatric-onset AML (M1-M5) and CML, while significantly lowly expressed
during complete remission of these diseases. MTT assay indicated that the proliferations of K562 and HL60 cells
were significantly promoted by miR-99a, and apoptosis assessment by Annexin V/propidium iodide staining
demonstrated that the apoptosis of these cells was inhibited by miR-99a. Additionally, dual-luciferase reporter
transfection assay and western blot analysis indicated that miR-99a may target CTDSPL and TRIB2, which are two
tumor suppressor genes.
Conclusions: This study revealed that miR-99a may play a potential oncogenic role in pediatric myeloid leukemia
including AML and CML via regulating tumor suppressors CTDSPL and TRIB2, suggesting that these two leukemias
might share some common biological pathways involved in the generation and development of disease and miR-
99a could be a common therapeutic target for myeloid leukemias treatment.
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Leukemia is one of the leading causes of cancer death
worldwide. Acute myeloid leukemia (AML), one type of
malignant diseases, arises from myeloid progenitor cells
that are arrested at early stages of differentiation.
Chronic myeloid leukemia (CML) is a clonal disorder in
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reproduction in any medium, provided the orclonal expansion. Although the recent advancement in
understanding and treatment of AML and CML has re-
markably improved the cure rate over the past decade, a
number of patients still die of these diseases. This high-
lights the need for more thorough knowledge of these
two leukemias.
Recently, microRNAs (miRNAs), a class of non-coding
RNA, were found to play important roles in various fun-
damental biological processes, such as cell proliferation,
apoptosis, differentiation and signaling pathway, which
are accomplished by silencing specific target genes
through translational repression or direct mRNA deg-
radation [1-3]. Studies demonstrated that about 50% of
annotated human miRNAs are located at fragile sitesLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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NAs are involved in cancer regulation and are consid-
ered as oncogenes or tumor suppressors [5]. The
expression profiles of miRNAs could be linked to disease
diagnosis, therapeutic response and prognosis [6-10].
The first finding linking miRNAs and leukemia was that
adult patients with chronic lymphocytic leukemia often
have deletions or downregulation of miR-15 and miR-16
at 13q14 [11]. Up to date, an increasing number of stud-
ies have revealed that the differentiation of AML line-
ages is regulated by miRNAs, which have key roles in
hematopoiesis [12,13].
Our previous miRNA profiling analysis showed the ex-
pression of miR-99a in pediatric-onset AML (FAB M1-
M3) was 3.81 times higher at average than that in nor-
mal donors [14], suggesting miR-99a may be involved in
the progression of pediatric myeloid leukemia. To con-
firm this, we performed further investigation to assess
the expression of miR-99a in childhood AML and CML,
and the function of miR-99a in these diseases.Methods
Clinical samples
A total of 88 bone marrow samples were enrolled in this
study. The samples taken by bone marrow puncture
were from 68 pediatric acute myeloid leukemia patients
(including 41 samples before therapy, 23 samples with
complete remission and 4 samples with relapse), 8
chronic myeloid leukemia patients (including 4 samples
before therapy and 4 samples with complete remission)
and 12 pediatric controls from the First and Second Af-
filiated Hospital of Sun Yat-Sen University. The newly
diagnosed AML patients included 6 with M1, 17 with
M2, 10 with M3, 4 with M4 and 4 with M5. The AML
patients with complete remission (CR) included 1 with
M1, 6 with M2, 6 with M3, 6 with M4 and 4 with M5.
The relapsed AML patients were 4 with M2. Patients’
characteristics are shown in Additional file 1: Tables S1
and S2. Written informed consent for biological studies
was obtained and the study was approved by the Ethics
Committee of the affiliated hospitals of Sun Yat-Sen
University.Cell culture and RNA/protein isolation
Human HL60 (acute myeloid leukemia cell line) and
K562 cells (chronic myeloid leukemia cell line) were cul-
tured in RPMI 1640 medium (Invitrogen). HEK-293 T,
the human embryonic kidney cell line, was grown in
Dulbec-co’s modified Eagle’s medium (Invitrogen). Both
cultures were supplemented with 10% fetal bovine serum
(fetal bovine serum, Australia) and sodium pyruvate, and
cultured at 37°C in a humidified atmosphere consisting
of 5% CO2. Total RNA and protein were isolated fromclinic samples with Trizol (Invitrogen, Carlsbad, CA) ac-
cording to the instructions of the manufacturer.
Quantitative real-time PCR analysis for miR-99a
expression
Quantitative real-time reverse transcriptase PCR (qRT-
PCR) was performed to detect miR-99a expression.
Briefly, 0.2 μg of small RNA extracted from cell samples
was reverse-transcribed to cDNA using M-MLV reverse
transcriptase (Promega) and amplified with specific de-
signed miRNA RT-primers and PCR amplification
primers (Sangon, Shanghai, China). Sequences of all the
primers are shown in Additional file 1: Table S3. The ex-
pression level of each miRNA was measured using the
2-DeltaDeltaCt method.
MTT assay
K562 and HL60 cells were respectively plated at 1 × 104
per well. The cells were transfected with 100 nM miR-
99a mimics/NC (miR-99a/scrambled oligonucleotides)
or inhibitor-miR-99a/NC using Lipofectamine 2000
(Invitrogen) following manufacturer’s recommendation
and were then incubated for 24 h, 48 h and 72 h, re-
spectively. Next, the cells were incubated with Dye Solu-
tion (15 μL) for another 4 h until purple precipitate was
visible. Lastly, after 100 μL Stop Mix was added, the
cells were left at room temperature in the dark for 2 h
and the absorbance was recorded.
Apoptosis assay
K562 and HL60 cells were transfected with miR-99a
mimics/NC or inhibitor-miR-99a/NC (100 nM) using Li-
pofectamine 2000 as mentioned above. The cells were
collected at 48 h, 72 h and 96 h post transfection re-
spectively. The cells were centrifuged and resuspended
in 500 μl of staining solution (containing annexin V
fluorescein and propidium iodide in HEPES buffer)
(annexin V: FITC apoptosis detection kit; BD PharMin-
gen, San Diego, CA). After incubation at room
temperature for 15 min, cells were analyzed by flow
cytometry.
Target genes prediction and vector constructs
The potential targets of miR-99a were predicted by
means of TargetScan (http://www.targetscan.org/) and
PICTAR (http://pictar.mdc-berlin.de/) software. In order
to reduce the number of false positives, only putative
target genes predicted by both programs were accepted.
The vectors of pre-miR-99a and the potential targets
predicted (TRIB2 and CTDSPL) were constructed.
Briefly, the primers of miR-99a were designed to amplify
pre-miR-99a by PCR from genomic DNA. The amplified
products were ligated into the PCD6.2 vector (Promega,
Madison, WI). Ecological forms and mutants of the
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and generated by annealing, were ligated into the pGL3
vector or the psi-CHECK-2 vector (Promega, Madison,
WI). Proper insertions were all confirmed by DNA sequen-
cing. All the primers were synthesized (Sangon, Shanghai,
China) and the information is available in Additional file 1:
Table S4.
Cell transfections and Luciferase assays
HEK-293 T cells were grown in 24-well plates at a
density of 1 × 105 cells per well in 0.5 ml of complete
growth medium and allowed HEK-293 T cells to ad-
here overnight. K562 cells were grown in 24-well
plates at a density of 1 × 106 cells per well. 0.1 μg of
pre-miR-99a and the potential targets vectors were
transfected into HEK-293 T cells using Lipofectamine
2000 (Invitrogen) and were transfected into K562 cells
by electroblotting (Ambion, Austin, Texas) respect-
ively in growth medium according to manufacturer’s
recommendation. After 24-48 h, the transfected cells
were harvested for Dual-luciferase reporter transfec-
tion assay. Similarly, 100 nM miR-99a mimics/NC
duplex or inhibitor/inhibitor-NC were used for
transfection.
Western immunoblotting
K562 and HL60 cells were treated as indicated in the
figures and lysed in RIPA buffer (Pierce, Rockford, IL,
USA) with protease and phosphatase inhibitors
(Roche, Beijing, China). The protein of bone marrow,
K562 and HL60 cells was quantified using the BCA
protein assay (Pierce, Rockford, Illinois). Protein
(30 μg) was loaded onto a 12% SDS–PAGE gel then
transferred onto nitrocellulose. The membrane was
blocked for 2 h in Tris-buffered saline Tween-20
(TBST) containing 2% bovine serum albumin, and
cleaved parp was incubated with rabbit anti-CTDSPL
(1:10000, Cell Signaling, Danvers, MA) and mouse
anti-TRIB2 (1:5000, Abcam, Invitrogen, USA) over-
night at 4°C. After incubation with HRP-conjugated
secondary anti-mouse or anti-rabbit (ABR, Golden,
Colorado) at room temperature for 1 h, blots were
then developed according to ECL Substrate (Pierce)
following manufacturer’s instructions. Protein was
normalized with β-actin (Sigma St. Louis, Missouri),
Tublin (Cell Signaling Technology, USA) and GAPDH
(Cell Signaling Technology, USA), and measured by
densitometry by two independent researchers.
Statistical analysis
T test, ANOVA and non-parametric rank sum test were
performed using SPSS16.0 statistical software. A Fisher
r-to-z transformation was carried out to calculate aprobability level (P value). Student’s t test was performed
to assay the statistical significance.
Results
MiR-99a is highly expressed in pediatric AML and CML at
diagnosis, while significantly lower expressed during
complete remission of the diseases
To investigate miR-99a expression in different subtypes
and disease stages of pediatric AML, qRT-PCR was per-
formed on 62 bone marrow samples including 12
pediatric controls, 23 newly diagnosed (only 23 samples
of 41 newly diagnosed AML patients available due to
poor quality or limited amouts of RNA), 4 relapse and
23 CR patients, all of which were not in pairs. The 23
newly diagnosed patients included 2 with M1, 7 with
M2, 6 with M3, 4 with M4 and 4 with M5. Results
showed that miR-99a was highly expressed in all of the
onset patients with M1 to M5, however, in 91% of the
CR patients, miR-99a expression decreased sharply to a
level similar to that in normal controls (Figure 1A). In
addition, the expression of miR-99a in the relapsed pa-
tients with M2 increased obviously, and was even higher
than that of their onset counterpart (Figure 1A).
For CML, a total of 20 bone marrow samples includ-
ing 12 pediatric controls and 8 CML children (4 at newly
diagnosis and 4 in CR), were also used for qRT-PCR.
The results displayed that miR-99a expression signifi-
cantly increased in all cases at diagnosis (median 5.21),
while distinguishedly decreased in those during CR (me-
dian 0.71). The former was 7.34 times of the latter
(Figure 1B). Moreover, qRT-PCR revealed the expression
of miR-99a in K562 cells, a CML cell line, was approxi-
mately 9.54 times of that in CR patients. Therefore, it
was inferred that miR-99a might be involved in prolifer-
ation and apoptosis of myeloid leukemia.
MiR-99a promotes the proliferation and inhibits the
apoptosis of HL60 and K562 cells
In order to further elucidate and prove whether miR-99a
may function as an oncogene in pediatric AML and
CML, the proliferation of HL60 and K562 cells was mea-
sured by MTT assay when miR-99a was overexpressed
or downexpressed respectively.
HL60 and K562 cells were transfected with miR-99a or
a random sequence of non-mammalian miRNA chain
(negative control, NC), and were cultured for 24 h, 48 h,
72 h and 96 h, respectively. The survival rates of HL60
and K562 cells were then measured at 570 nm. Each ex-
periment was repeated for four times. Figure 2A and 2C
showed that cell survival rates in miR-99a groups are
significantly higher than those in NCs and reach a peak
after culture for 72 h. The proliferation of HL60 and
K562 cells was stimulated by the overexpression of miR-
99a, and this effect was time-dependent. Meanwhile, the
Figure 1 The expression of miR-99a assessed by real-time qRT-PCR in pediatric AML (M1-M5) (A) and CML (B) patients before and after
therapy. The data were normalized against U6 expression in the same patient. *P < 0.05, **P < 0.01. There was only one patient with AML-M1
available for evaluation and thus no statistical analysis was performed.
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inhibitor-miR-99a were significantly decreased (Figure 2B
and 2D). These suggest that miR-99a can promote the
proliferation of HL60 and K562 cells. In addition, to
check the transfection efficiency, labeled negative con-
trol was transfected into HL60 and K562 cells respect-
ively under the same conditions. Additional file 2: Figure
S1 demonstrates high transfection efficiency at 36 h after
transfection.
Since the study above suggested that miR-99a could pro-
mote the proliferations of HL60 and K562 cells, we then
further assessed whether miR-99a could suppress the apop-
tosis of HL60 and K562 cells. Apoptosis assessment by
Annexin V/propidium iodide staining was performed.Figure 2 MiR-99a promotes the proliferation of HL60 and K562 cel
inhibitor-miR-99a or corresponding negative control respectively. MTT a
HL60 (A) and K562 (C) cells, and inhibitor-miR-99a reduces the proliferaHL60 and K562 cells were collected at 48 h, 72 h and 96 h
were analyzed by flow cytometry, respectively. As expected,
Figure 3 showed that the apoptotic rates of both HL60 and
K562 cells are lower in miR-99a groups and higher in
inhibitor-miR-99a groups when compared with their corre-
sponding NCs, although significant difference of the apop-
totic rates were observed only in K562 cells between miR-
99a and NC groups, and in HL60 cells between inhibitor-
miR-99a and NC groups, respectively.
Taken together, these data indicated that miR-99a
might function as a potential oncogene and contribute
to pediatric AML and CML progression by promoting
proliferation and inhibiting apoptosis of myeloid
leukemic cells.ls. HL60 and K562 cells were transfected with miR-99a mimics,
ssay shows miR-99a significantly promotes the proliferation of the
tion of the HL60 (B) and K562 (D) cells. *P < 0.05.
Figure 3 MiR-99a inhibits the apoptosise of HL60 and K562
cells. Apoptosis assessment by Annexin V/propidium iodide staining
shows the apoptotic rates of K562 and HL60 cells transfected with
miR-99a mimics, inhibitor-miR-99a or corresponding NC respectively.
The fourth quadrant represents apoptotic cells detected by flow cy-
tometry. (A, B) Of the K562 cells measured at 72 h after transfection,
miR-99a inhibits apoptosis and the inhibition rate is 50.3%. (A) miR-
99a NC, (B) miR-99a mimics. P < 0.05. (C, D) Of the K562 cells at
48 h, inhibitor-miR-99a prevents the inhibition of apoptosis and the
prevention rate is 24%. (C) inhibitor-miR-99a NC, (D) inhibitor-miR-
99a mimics. P > 0.05. (E, F) Of the HL60 cells at 96 h, miR-99a inhibits
apoptosis and the inhibition rate is 18.5%. (E) miR-99a NC, (F) miR-
99a mimics. P > 0.05. (G, H) Of the HL60 cells at 48 h, inhibitor-miR-
99a prevents the inhibition of apoptosis and the prevention rate is
50%. (G) inhibitor-miR-99a NC, (H) inhibitor-miR-99a mimics. P < 0.05.
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As we know, a large number of studies have shown that
miRNAs play roles through their downstream target
genes. In order to reduce the number of false positives,
only putative target genes predicted by both programs
were accepted. Among them, CTDSPL and TRIB2 are
closely associated with leukemia cell apoptosis and were
chosen to be further validated in HEK-293 T cells using
luciferase reporter assays. Figure 4A and 4B show that
the predicted miR-99a-binding sites in 3’UTR of
CTDSPL and TRIB2 .
CTDSPL, the protein of carboxy-terminal domain
RNA polymerase II polypeptide A small phosphatase
(CTDSP) family, is a recently identified phosphatase-like
tumor suppressor gene [15]. A current research showed
that CTDSPL relates to the regulation of cell growth and
differentiation, and frequent mutations or deregulation
of this gene are disclosed in human hematopoietic cell
and myeloid leukemia cell lines [16,17]. TRIB2 has 3 dis-
tinct regions, proline-rich N-terminus, serine/threonine
kinase homology domain and C-terminal constitutive
photomorphogenesis 1 (COP1)-binding domain. It acts
as either a tumor suppressor or a cancer promoter in
different biological conditions. We observed that when
the wild-types of CTDSPL and TRIB2 were respectively
co-transfected with miR-99a precursor into HEK-293 T
cells, their luciferase activities were obviously suppressed
by 51-53% and 45-49%, respectively (Figure 4C). There-
fore, CTDSPL and TRIB2 may be the target genes of
miR-99a.
Furthermore, the wild-type of CTDSPL or TRIB2, or the
mutations of CTDSPL or TRIB2, deleting the seed se-
quence, was co-transfected with miR-99a precursor into
HEK-293 T cells respectively. Results showed that the miR-
99a precursor suppressed the luciferase activity of the wide
type CTDSPL by 58-61% and the luciferase activity of the
wide type TRIB2 by 53-54%. However, the full mutations of
CTDSPL and TRIB2 abrogated the repressive ability of
miR-99a, demonstrating the specificity of miR-99a target
sequence in CTDSPL and TRIB2 (Figure 4D and 4E). As
shown in Additional file 2: Figure S2, we can observe that
HEK-293 T cells maintained in good condition and dis-
played high transfection rate, indicating the high accuracy
and reliability of the experimental results.
CTDSPL and TRIB2 were preliminarily confirmed as
two target genes of miR-99a in HEK-293 T cells. In
K562 cells, a leukemic line, further verification experi-
ments were carried out. The results were consistent with
those found in HEK-293 T cells (Figure 4F and 4G).
Additional file 2: Figure S3 showed that K562 cells were
in good condition and displayed high transfection rate.
In addition, the ability of miR-99a to regulate the en-
dogenous CTDSPL and TRIB2 proteins was tested. Results
showed that the expression of CTDSPL protein decreased
Figure 4 MiR-99a Target genes prediction, selection and verification. (A, B) The putative miR-99a target sequences in CTDSPL and TRIB2
genes respectively. (C) When CTDSPL or TRIB2 cloned into pGL3 vector was co-transfected into HEK-293 T cells with miR-99a precursor which
had been cloned into pCD6.2 vector, luciferase activity was suppressed by 51-53% or 45-49% respectively. (D, E) MiR-99a target genes verification.
Both the wild type and the full mutation of CTDSPL and TRIB2 were synthesized. When the wild-type of CTDSPL or TRIB2 was co-transfected with
miR-99a precursor into HEK-293 T cells, luciferase activity was suppressed by 58-61% or 53-54% respectively. (F, G) Further verification of miR-99a
Target genes (CTDSPL and TRIB2) through luciferase reporter assay in K562 cells by electroporation. Error bars represent standard deviation and
each data was obtained from three independent experiments. *P < 0.05. **P < 0.01.
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tured for 4 days, compared with the cells tranfected with
NC duplex (Figure 5A and 5B). Similarly, the expression of
TRIB2 protein also decreased in K562 cells transfected with
miR-99a (Figure 5C), however, increased significantly in
the cells transfected with inhibitor-miR-99a compared
with those transfected with inhibitor-NC (Figure 5D).Collectively, it is strongly suggested that miR-99a targets
and suppresses CTDSPL and TRIB2 [17-19].
MiR-99a represses expression of CTDSPL and TRIB2
proteins in most clinical samples from AML patients
Based on the experimental results mentioned above, we
assumed that the expressions of CTDSPL and TRIB2
Figure 5 Role of miR-99a in expressions of CTDSPL and TRIB2 proteins in HL60 or K562 cells. The expression of CTDSPL in HL60 (A) or
K562 (B) cells transfected with 100 nM miR-99a mimics or NC duplex, respectively. The expression of TRIB2 in K562 cells transfected with 100 nM
miR-99a mimics or NC duplex (C), or 100 nM inhibitor-miR-99a or inhibitor-NC (D), respectively.
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those in CR, which is contrary to the expression of miR-
99a. A total of 38 bone marrow samples that had suffi-
cient cell material available were used to determine the
expression of CTDSPL by western blot, which were from
4 controls and 34 AML patients with M2 and M3 (15 at
diagnosis, 19 in hematological CR, all of which were not
in pairs). As expected, the expression level of CTDSPL
was relatively high in control group and in 58% of the
patients with CR; however, it was down-regulated in
86.6% of the patients at diagnosis (Figure 6A, 6B and
Additional file 2: Figure S4). In addition, a total of 30
samples that had sufficient cell material available were
used to determine the expression of TRIB2 protein, in-
cluding 2 controls and 28 AML patients with M2 and
M3 (15 at diagnosis and 13 with hematological CR, not
in pairs). Results showed that the expression level of
TRIB2 protein was relatively high in control group and
in 69.2% of the patients with CR, while the expression
level decreased in 73.7% of the patients at diagnosis
(Figure 6C, 6D and Additional file 2: Figure S5). All
these further support that miR-99a targets CTDSPL and
TRIB2 genes.
In conclusion, our study indicates that miR-99a may
play an oncogenic role by targeting the tumor suppres-
sors CTDSPL and TRIB2 in most pediatric myeloid
leukemia.
Discussion
Leukemia is the commonest childhood malignant disease.
With the rapid development of modern combination
chemotherapy and hematopoietic stem cell transplantation,
5-year event-free survival for pediatric acute lymphoblastic
leukemia (ALL) has been improved to rates as high as 80%
[20,21]. However, the prognosis of pediatric AML is still
poor, with long-term survival rates of about 50% to 65%
[22]. The overall survival of CML was recently reported to
be up to 80% at 8 years of follow-up in respondent patientsdue to the introduction of imatinib (a tyrosine kinase in-
hibitor) [23], there still remains a subset of patients who fail
the treatment. It is therefore of significance to clarify the
molecular mechanisms of these two diseases for further im-
proving survival rate. For a long time, the pathogenesis re-
searches of AML and CML mainly focus on chromosome
abnormalities and protein coding genes. Recently, more
and more studies indicated that abnormal expressions of
relevant miRNAs may promote tumors. Their abnormal
expressions are closely related to the incidence, develop-
ment, treatment response and prognosis of leukemia
[11,24-28]. Although some miRNA expression signatures
associated with types and cytogenetics of leukemia have
been addressed, there has been no report on miR-99a ex-
pressional and functional study in pediatric AML and CML
so far.
In this study, we found that the expression of miR-99a
increased significantly not only in childhood patients
with AML (M1-M5) but also in those with CML, de-
creased obviously in CR patients with these two myeloid
leukemias, and increased again in relapsed patients with
AML-M2 analyzed. Furthermore, MTT assay showed
that the proliferation of K562 and HL60 cells was effect-
ively promoted by miR-99a, and apoptosis experiment
demonstrated that the apoptosis of K562 and HL60 cells
was suppressed by miR-99a. These results illustrate that
miR-99a may function as an oncogene, which contrib-
utes to the generation and development of both AML
and CML in children. Finally, dual-luciferase reporter
transfection assay and western blot analysis on clinical
samples and leukemia cell lines further supported that
miR-99a played a potential oncogene role by targeting
CTDSPL and TRIB2 in most pediatric myeloid leukemia
patients.
CTDSPL gene exhibits tumor suppressor gene activity.
It has been reported that CTDSPL protein plays the role
of phosphatase, regulating cells growth and differenti-
ation, and expresses significantly low in major epithelial
Figure 6 MiR-99a represses expression of CTDSPL and TRIB2 proteins in most clinical samples from AML patients. Western blot showed
that the expression level of CTDSPL protein in patients with AML-M3 (A) and AML-M2 (B) and the expression level of TRIB2 protein in patients
with AML-M3 (C, D) were relatively high in children in control group (N) and most of the patients in hematological CR; however, the level de-
creased in most of the patients before treatment (P).
Zhang et al. Cancer Cell International 2013, 13:110 Page 8 of 11
http://www.cancerci.com/content/13/1/110malignancies [15]. In leukemia cell lines and 24% of pa-
tients with acute lymphoblastic leukemia, CTDSPL pro-
moter is highly methylated, which promotes the
occurrence of leukemia [29]. A study further revealed
that RBSP3, also denoted as HYA22 and CTDSPL, is in-
volved in the regulation of cell growth and differenti-
ation, and frequent mutations in this gene are detected
in human hematopoietic cell lines [16]. The tumor sup-
pressor property of CTDSPL is related to its ability to
remove the phosphate group from serine 807 and 811,
and induce the formation of the RB-E2F1 complex [30].
The ‘RB’ pathway has a critical role in both cell physi-
ology and tumorigenic transformation via distinct mo-
lecular mechanisms.
TRIB2, like some other genes, has distinctive roles in
different biological conditions. On the one hand, TRIB2,
a pseudokinase, may function as an oncogene and coop-
erates with HoxA9 to accelerate the onset of AML in
mice by binding COP1 and C/EBP-α and leading to deg-
radation of C/EBP-α [31-33]. On the other hand, TRIB2
may serve as a tumor suppressor gene. A resent report
showed that forced expression of PITX1 in JURKATcells prompted deregulation of genes involved in T-cell
development including TRIB2. Leukemic activation of
PITX1 was observed in a subset of early-staged T-ALL
by inhibiting T-cell development [34]. TRIB2 is also a
pro-apoptotic molecule and activates Bax gene to induce
apoptosis in hematopoietic cells through degradation of
MCL-1 [35]. Its tumour suppressor activity may be abro-
gated in a proportion of AML patients, which may lead
to enhanced cell survival and therefore contribute to
pathogenesis of the disease [36].
MiR-99a has been addressed to be involved in the
tumorigenesis of several cancers. MiR-99a may play dif-
ferent roles in different tumors. Wong and Wszolek re-
ported that miR-99a expresses notably high in untreated
patients with tongue squamous cell carcinoma and non-
invasive urothelial cancer, suggesting that miR-99a ex-
hibits oncogenic activity [37,38]. However, Yamada et al.
addressed that the expression of miR-99a deceased in
onset patients with lung cancer, implying that miR-99a
may behave as a tumor suppressor gene [39]. In this
study, we find that miR-99a plays a potential oncogenic
role in pediatric AML and CML through targeting
Zhang et al. Cancer Cell International 2013, 13:110 Page 9 of 11
http://www.cancerci.com/content/13/1/110CTDSPL and TRIB2. All the above studies elucidate that
the roles of certain miRNAs are completely distinctive in
different biological conditions, which is also supported
by some other studies [18,19,40-43]. All these highlight
the importance of thoroughly studying and comprehen-
sively expounding the expression and function of miR-
NAs in different tumors as well as the same tumor in
adults and children.
It is noted that in this study there was a relatively lar-
ger number of clinical samples which were tested for the
expressions of miR-99a, CTDSPL and TRIB2 compared
with previous studies. The results revealed that miR-99a
may target CTDSPL and TRIB2 more convincingly from
a statistical point of view. However, the results also
showed that CTDSPL or TRIB2 protein and miR-99a ex-
hibited opposite expression trends in most the patients,
but not in all the patients, indicating that CTDSPL and
TRIB2 genes are not the only target genes of miR-99a.
Therefore, there may be other potential undiscovered
target genes, which is in line with our present know-
ledge. As a single miRNA could regulate several different
genes and the same gene could also be regulated by sev-
eral miRNAs [44,45], the regulation of miRNA forms a
complex network. The complicated interactions of rele-
vant miRNAs contribute to the occurrence and develop-
ment of leukemia.
Conclusions
This is the first report to demonstrate the expression
and function of miR-99a in childhood AML and CML.
MiR-99a targets CTDSPL and TRIB2, and regulates their
expressions in most childhood AML and CML, which
may reveal a new post-transcriptional mechanism of
regulation in the myeloid lineage. Additionally, this
study suggests that there might be some common bio-
logical pathways involved in disease development of
AML and CML although they are two clinically different
myeloid leukemias and miR-99a could be a common
therapeutic target for the treatment of these two myeloid
leukemias.
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with PCD6.2 vector (A) and fluorescence in the HEK-293 T cells (B) at 28 h
after transfection. Figure S3. K562 cells transfected with PCD6.2 vector
(A) and fluorescence in the K562 cells (B) at 28 h after transfection.
Figure S4. MiR-99a represses expression of CTDSPL proteins in most
clinical samples from AML patients. In patients with AML-M3 (A, B) andAML-M2 (C, D), western blot showed that the expression level of CTDSPL
protein was relatively high in children in control group (N) and most of
the patients in hematological CR; however, the level decreased in most
of the patients before treatment (P). Figure S5. MiR-99a represses
expression of TRIB2 proteins in most clinical samples from AML patients.
In patients with AML-M2 (A-C), western blot showed that the expression
level of TRIB2 protein was relatively high in children in control group (N)
and most of the patients in hematological CR; however, the level
decreased in most of the patients before treatment (P).
Abbreviations
AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia;
qRT-PCR: Quantitative real-time reverse transcriptase PCR; miRNA: MicroRNA;
CTDSP: CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A)
small phosphatase-like; TRIB2: Tribbles homolog 2 (Drosophila);
MCL-1: Myeloid cell leukemia sequence 1 (BCL2-related).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LDZ performed experiments, analyzed the data and wrote the manuscript;
XJL, YNL JW and XLZ performed a part of western blot; ZYK and LBH
provided samples for the analysis; YQC, HZ and XQL designed experiments
and edited the manuscript. All authors critically reviewed the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by National Science and Technology Department
(2011CBA01105, 2011CB811301 and 2009ZX09103-641) and the funds from
National Natural Science Foundation of China (81070440 and 81300398), Sci-
ence and Technology Planning Project of Guangdong Province, China
(2008B030301104) and Supported by Medical Scientific Research Foundation
of Guangdong Province, China (A2012176).
Author details
1Department of Pediatric, The First Affiliated Hospital of Sun Yat-Sen
University, Zhongshan Er Lu, Guangzhou 510080, China. 2Key Laboratory of
Gene Engineering of the Ministry of Education, State Key Laboratory for
Biocontrol, Sun Yat-Sen University, Guangzhou 510275, China.
3China-America Cancer Research Institute, Key Laboratory for Medical
Molecular Diagnostics of Guangdong Province, Guangdong Medical College,
1 Xincheng Road, Song-Shan Lake (SSL) Science, Technology and Industrial
Park, Dongguan, Guangdong 523808, China.
Received: 4 July 2013 Accepted: 1 November 2013
Published: 5 November 2013
References
1. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 116:281–297.
2. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP,
Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs
downregulate large numbers of target mRNAs. Nature 2005, 433:769–773.
3. Virtue A, Wang H, Yang XF: MicroRNAs and toll-like receptor/interleukin-1
receptor signaling. J Hematol Oncol 2012, 5:66.
4. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S,
Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA
genes are frequently located at fragile sites and genomic regions
involved in cancers. Proc Natl Acad Sci USA 2004, 101:2999–3004.
5. Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med
2005, 353:1768–1771.
6. Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, Andrén O,
Olsson B, Klinga-Levan K: A miRNA expression signature that separates
between normal and malignant prostate tissues. Cancer Cell Int 2011,
11:14.
7. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F,
Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G,
Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM:
Zhang et al. Cancer Cell International 2013, 13:110 Page 10 of 11
http://www.cancerci.com/content/13/1/110MicroRNA signatures associated with cytogenetics and prognosis in
acute myeloid leukemia. Blood 2008, 111:3183–3189.
8. Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL,
Scheucher PS, Oliveira LC, Dalmazzo LF, Silva-Júnior WA, Falcão RP, Rego
EM: Increased expression of miR-221 is associated with shorter overall
survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol. 2013, 2:10.
9. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland
KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell
BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA,
Larson RA, Bloomfield CD: BAALC and ERG expression levels are
associated with outcome and distinct gene and microRNA
expression profiles in older patients with de novo cytogenetically
normal acute myeloid leukemia: a Cancer and Leukemia Group B
study. Blood 2010, 116:5660–5669.
10. Labbaye C, Testa U: The emerging role of MIR-146A in the control of
hematopoiesis, immune function and cancer. J Hematol Oncol 2012, 5:13.
11. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S,
Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM: Frequent
deletions and down -regulation of micro-RNA genes miR15 and miR16 at
13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002,
99:15524–15529.
12. Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, Liu M, Zou Y, Weissman IL,
Gu H: MicroRNA-29a induces aberrant self-renewal capacity in hematopoietic
progenitors, biased myeloid development, and acute myeloid leukemia. J Exp
Med 2010, 207:475–489.
13. Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F: MiR-424 and miR-
155 deregulated expression in cytogenetically normal acute myeloid leu-
kaemia: correlation with NPM1 and FLT3 mutation status. J Hematol
Oncol 2012, 5:26.
14. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH,
Xu L, Chen YQ: MicroRNA Patterns Associated with Clinical Prognostic
Parameters and CNS Relapse Prediction in Pediatric Acute Leukemia.
Plos One 2009, 4:e7826.
15. Kashuba VI, Li J, Wang F, Senchenko VN, Protopopov A, Malyukova A,
Kutsenko AS, Kadyrova E, Zabarovska VI, Muravenko OV, Zelenin AV, Kisselev
LL, Kuzmin I, Minna JD, Winberg G, Ernberg I, Braga E, Lerman MI, Klein G,
Zabarovsky ER: RBSP3 (HYA22) is a tumor suppressor gene implicated in
major epithelial malignancies. Proc Natl Acad Sci USA 2004,
101:4906–4911.
16. Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, Lin KY, Zhou H,
Qu LH, Zhang P, Chen YQ: MiR-100 regulates cell differentiation and
survival by targeting RBSP3, a phosphatase-like tumor suppressor in
acute myeloid leukemia. Oncogene 2012, 31:80–92.
17. Kashuba VI, Pavlova TV, Grigorieva EV, Kutsenko A, Yenamandra SP, Li J,
Wang F, Protopopov AI, Zabarovska VI, Senchenko V, Haraldson K,
Eshchenko T, Kobliakova J, Vorontsova O, Kuzmin I, Braga E, Blinov VM,
Kisselev LL, Zeng YX, Ernberg I, Lerman MI, Klein G, Zabarovsky ER: High
mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL)
in cancer. PLoS One 2009, 4:e5231.
18. He L, Thomson JM, Hemann MT: A microRNA polycistron as a potential
human oncogene. Nature 2005, 435:828–833.
19. Hayashita Y: A polycistronic microRNA cluster, miR-17-92, is over-
expressed in human lung cancers and enhances cell proliferation.
Cancer Res 2005, 65:9628–9632.
20. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G,
Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E: Long-
term results of large prospective trials in childhood acute lymphoblastic
leukaemia. Leukaemia 2000, 14:2193–2194.
21. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner
H, Odenwald E, Riehm H: Long-term results of four consecutive trials in
childhood ALL performed by the ALL-BFM study group from 1981 to 1995.
Berlin-Frankfurt-Munster. Leukaemia 2000, 12:2205–2222.
22. Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D,
Döhner H, Schlenk RF: Significance of age in acute myeloid
leukemia patients younger than 30 years: a common analysis of
the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/
99 and AMLSG HD93/98A. Cancer 2008, 112:562–571.
23. Breccia M, Alimena G: How to treat CML patients in the tyrosine kinase
inhibitors era? From imatinib standard dose to second generation drugs
front-line: unmet needs, pitfalls and advantages. Cancer Lett 2012,
322:127–132.24. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV,
Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R,
Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM:
A MiRNA signature associated with prognosis and progression in chronic
lymphocytic leukemia. N Engl J Med 2005, 353:1793–1801.
25. Fernando TR, Rodriguez-Malave NI, Rao DS: MicroRNAs in B cell develop-
ment and malignancy. J Hematol Oncol 2012, 5:7.
26. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE,
Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ,
Negrini M, Croce CM: miR-15 and miR-16 induce apoptosis by targeting
BCL2. Proc Natl Acad Sci USA 2005, 102:13944–13949.
27. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I: A
minicircuitry comprised of miRNA-223 and transcription factors NFI-A
and C/EBP alpha regulates human granulopoiesis. Cell 2005, 123:819–831.
28. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero
A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub
TR: MiRNA expression profiles classify human cancer. Nature 2005,
435:834–838.
29. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP: Silencing
of bidirectional promoters by DNA methylation in tumorigenesis.
Cancer Res 2006, 66:5077–5084.
30. Ghosh A, Ghosh S, Maiti GP, Sabbir MG, Zabarovsky ER, Roy A,
Roychoudhury S, Panda CK: Frequent alterations of the candidate genes
hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck:
clinical and prognostic significance. Cancer Sci 2010, 101:1511–1520.
31. Keeshan K, Bailis W, Dedhia PH, Vega ME, Shestova O, Xu L, Toscano K,
Uljon SN, Blacklow SC, Pear WS: Transformation by Tribbles homolog 2
(Trib2) requires both the Trib2 kinase domain and COP1 binding.
Blood 2010, 116:4948–4957.
32. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, Rodriguez CG,
Maillard I, Tobias JW, Valk P, Carroll M, Aster JC, Delwel R, Pear WS: Tribbles
homolog 2 inactivates C/EBPalpha and causes acute myelogenous
leukemia. Cancer Cell 2006, 10:401–411.
33. Keeshan K, Shestova O, Ussin L, Pear WS: Tribbles homolog 2 (Trib2) and
HoxA9 cooperate to accelerate acute myelogenous leukemia.
Blood Cells Mol Dis 2008, 40:119–121.
34. Nagel S, Venturini L, Przybylski GK, Grabarczyk P, Schneider B, Meyer C,
Kaufmann M, Schmidt CA, Scherr M, Drexler HG, Macleod RA: Activation of
Paired-homeobox gene PITX1 by del(5)(q31) in T-cell acute lympho-
blastic leukemia. Leuk Lymphoma 2011, 52:1348–1359.
35. Cheng AM, Byrom MW, Shelton J, Ford LP: Antisense inhibition of human
miRNAs and indications for an involvement of miRNA in cell growth and
apoptosis. Nucleic Acids Res 2005, 33:1290–1297.
36. Gilby DC, Sung HY, Winship PR, Goodeve AC, Reilly JT, Kiss-Toth E: Tribbles-
1 and −2 are tumour suppressors, down-regulated in human acute mye-
loid leukaemia. Immunol Lett 2010, 130:115–124.
37. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI: Mature miR-184 as
Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue.
Clin Cancer Res 2008, 14:2588–2592.
38. Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK,
Logvinenko T, Libertino JA, Summerhayes IC: A MicroRNA expression pro-
file defining the invasive bladder tumor phenotype. Urol Oncol 2009,
26:2301–2306.
39. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H,
Nagino M, Takahashi T: Detailed characterization of a homozygously
deleted region corresponding to a candidate tumor suppressor locus at
21q11-21 in human lung cancer. Genes Chromosomes Cancer 2008,
47:810–818.
40. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M,
Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ,
Bullrich F, Negrini M, Croce CM: MicroRNA profiling reveals distinct
signatures in B cell chronic lymphocytic leukaemias. Proc Natl Acad Sci
USA 2004, 101:11755–11760.
41. Shao Y, Qu Y, Dang S, Yao B, Ji M: MiR-145 inhibits oral squamous cell
carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell
Int 2013, 13:51.
42. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R,
Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A,
Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression
signature of human solid tumours defines cancer gene targets. Proc Natl
Acad Sci USA 2006, 103:2257–2261.
Zhang et al. Cancer Cell International 2013, 13:110 Page 11 of 11
http://www.cancerci.com/content/13/1/11043. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X,
Hyslop T, McCue P, Pestell RG: A cyclin D1/microRNA 17/20 regulatory
feedback loop in control of breast cancer cell proliferation. J Cell Biol
2008, 182:509–517.
44. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P,
da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combinatorial microRNA
target predictions. Nat Genet 2005, 37:495–500.
45. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES,
Kellis M: Systematic discovery of regulatory motifs in human promoters
and 3' UTRs by comparison of several mammals. Nature 2005,
434:338–345.
doi:10.1186/1475-2867-13-110
Cite this article as: Zhang et al.: MiR-99a may serve as a potential
oncogene in pediatric myeloid leukemia. Cancer Cell International
2013 13:110.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
